Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a variety of serious or life-threatening diseases. Reata focuses on drugs with novel mechanisms of action that modulate important regulatory proteins, called transcription factors, that coordinate the cellular response to stressors by activating or suppressing the activity of many target proteins. The effects of AIM pharmacology have been documented in more than 200 scientific papers and are potentially relevant to a wide range of diseases.

Irving, US
64 (est)

Key People at Reata Pharmaceuticals

Warren Huff

Warren Huff

President and CEO

Reata Pharmaceuticals Locations

Irving, US

Reata Pharmaceuticals Metrics

Reata Pharmaceuticals Summary

Founding Date


Market capitalization

$550 M

Closing share price


Reata Pharmaceuticals Market Value History

Reata Pharmaceuticals News

Reata Pharmaceuticals Company Life